Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) and Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.
Profitability
This table compares Praxis Precision Medicines and Sunshine Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Praxis Precision Medicines | N/A | -66.90% | -60.30% |
| Sunshine Biopharma | -16.06% | -24.96% | -19.46% |
Earnings and Valuation
This table compares Praxis Precision Medicines and Sunshine Biopharma”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Praxis Precision Medicines | $8.55 million | 479.99 | -$182.82 million | ($12.90) | -12.72 |
| Sunshine Biopharma | $34.87 million | 0.20 | -$5.13 million | ($1.02) | -1.36 |
Sunshine Biopharma has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Praxis Precision Medicines has a beta of 2.82, indicating that its stock price is 182% more volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Praxis Precision Medicines and Sunshine Biopharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Praxis Precision Medicines | 2 | 0 | 9 | 3 | 2.93 |
| Sunshine Biopharma | 1 | 0 | 1 | 0 | 2.00 |
Praxis Precision Medicines presently has a consensus target price of $257.50, indicating a potential upside of 56.93%. Sunshine Biopharma has a consensus target price of $7.00, indicating a potential upside of 403.60%. Given Sunshine Biopharma’s higher probable upside, analysts clearly believe Sunshine Biopharma is more favorable than Praxis Precision Medicines.
Insider and Institutional Ownership
67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 0.0% of Sunshine Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Praxis Precision Medicines beats Sunshine Biopharma on 8 of the 15 factors compared between the two stocks.
About Praxis Precision Medicines
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
About Sunshine Biopharma
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
